Faustan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Faustan

What is Faustan?

Faustan is a medication belonging to the benzodiazepine class of drugs. It contains the active substance diazepam, which acts on the central nervous system to produce a calming effect. It is primarily utilized for its properties in reducing anxiety, inducing sedation, and relaxing muscles.

Mechanism of Action

The medication works by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that inhibits overactive nerve signaling. By increasing the efficiency of GABA, the drug helps to stabilize neurological activity, leading to a decrease in nervous tension and emotional agitation.

Clinical Applications

In clinical practice, Faustan is used across several therapeutic areas due to its versatile effects on the nervous system. Common applications include:

  • Anxiety Disorders: Management of severe or disabling anxiety states and short-term relief of symptoms associated with emotional distress.
  • Sleep Disturbances: Treatment of insomnia, particularly when it is associated with underlying anxiety.
  • Muscle Spasms: Relief of reflex muscle spasms caused by local trauma or neurological conditions such as spasticity.
  • Preoperative Sedation: Use as a premedication to help patients remain calm and relaxed before medical or dental procedures.
  • Acute Alcohol Withdrawal: Assistance in managing the symptoms of agitation and tremors during the detoxification process.
  • Convulsive Disorders: Use as an adjunctive therapy for certain types of seizure disorders.

Characteristics and Duration

Faustan is characterized by its relatively rapid onset of action and its long-lasting effects. Once processed by the body, it is converted into active metabolites that continue to exert a calming influence for an extended period. Because it stays in the system longer than some other medications in the same class, its effects may be felt well into the following day.

What side effects are possible with Faustan?

Possible side effects and safety information

The safety profile of Faustan (Diazepam) is structurally defined by its effects as a Central Nervous System (CNS) depressant and the limitations outlined in official regulatory documents. All reported adverse reactions and safety statements are classified based strictly on government prescribing information.

Adverse Reaction Scope

Classification System-Organ Class Examples of Listed Effects
Common Nervous System Disorders Drowsiness, fatigue, impaired coordination (ataxia), muscle weakness.
Uncommon Nervous System, Gastrointestinal Slurred speech, headache, confusion, nausea, constipation.
Rare/Serious Respiratory, Cardiovascular Respiratory depression, apnea, cardiovascular collapse, suicidal ideation.

Dose- and Exposure-Related Safety

Dependence and Withdrawal Risk The use of Diazepam carries a documented risk of tolerance, physical dependence, abuse, and addiction, which increases with the duration of treatment. Abrupt discontinuation or rapid dose reduction after continued use may precipitate an acute and protracted withdrawal syndrome.

Paradoxical Reactions A defined category of adverse reactions includes rare, unexpected hyperexcited states such as anxiety, rage, increased muscle spasticity, and hallucinations. These are officially noted as being more likely in older adults and children.

Safety-Related Restrictions

Faustan is formally contraindicated in patients with a known hypersensitivity to the drug, severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis (a muscle weakness disorder), and acute narrow-angle glaucoma. Extreme caution is required in older adults and very ill patients due to the heightened possibility of profound sedation, confusion, and potential for apnea or cardiac arrest. Risks during pregnancy include neonatal flaccidity, respiratory difficulties, and withdrawal symptoms in the newborn if used late in gestation.

Overdose and Emergency Response

The officially documented overdose presentations of Faustan (Diazepam) are primarily characterized by Central Nervous System (CNS) depression. This commonly manifests as drowsiness, mental confusion, impaired motor function (ataxia), impaired coordination, dizziness, and excessive sleepiness (sedation). Physiological systems affected include the CNS (with potential progression to coma) and the respiratory system (resulting in respiratory depression and hypotension).

The risk of life-threatening events, including profound sedation, respiratory depression, and death, is significantly increased by co-ingestion with other CNS depressants, such as alcohol or opioids. Regulatory documents note that elderly individuals and patients with limited pulmonary reserve face an increased possibility of apnea and cardiac arrest in an overdose scenario.

Official guidance mandates that individuals must seek emergency medical help right away or call the nearest hospital when symptoms progress to slowed or shallow breathing, breathing stops, or unresponsiveness (coma). Management is defined as symptomatic and supportive, requiring the availability of resuscitative equipment. The benzodiazepine antagonist flumazenil is also noted in the regulatory context as an agent for management.

Therapeutic Uses of Faustan

What Faustan Treats: Main Uses and Benefits

Faustan is commonly used across domains where additional symptomatic support is needed, addressing symptoms related to heightened physiological activity.

It is relevant for easing symptoms that interfere with daily functioning and those associated with acute or episodic changes. It plays a role in managing conditions characterized by periods of heightened symptoms, including anxiety disorders, certain seizure disorders, severe skeletal muscle spasms, and acute alcohol withdrawal syndrome.

Quick Fact: Managing Symptoms of Increased Motor Activity

Faustan is applied in addressing symptom clusters that create noticeable functional strain, such as convulsive activity and chronic spasticity, providing supportive relief when these symptoms become more noticeable.

It is considered relevant in contexts involving heightened systemic burden, such as before medical or surgical procedures. This approach helps patients cope more steadily with difficult episodes.

“This medication supports the patient during difficult episodes by easing distress and maintaining functional stability.”

Regulatory References

  1. NIH StatPearls Overview

Eligibility and Restrictions for Use

Official Eligibility Profile

Official regulatory documents define strict limitations and outright prohibitions on the use of Faustan (Diazepam) based on age, pre-existing health conditions, and physiological status.

Category Regulatory Status
Populations Contraindicated Patients with known hypersensitivity to Diazepam, myasthenia gravis, severe hepatic insufficiency, severe respiratory insufficiency, sleep apnea syndrome, and acute narrow-angle glaucoma must not use this medicine.
Age-Related Rules Oral forms are contraindicated in pediatric patients under 6 months of age. Older adults require extreme caution and often need lower starting doses due to increased sensitivity and slower elimination.
Reproductive Status Use during pregnancy is generally not recommended due to potential fetal risk, which includes neonatal sedation and withdrawal syndrome if used late in pregnancy. Use during lactation requires monitoring or suspension of breastfeeding.
Condition Restrictions The medicine is not recommended for the treatment of psychotic patients. Patients with mild-to-moderate hepatic impairment or compromised kidney function require caution due to altered drug clearance. Individuals with a history of substance abuse require pre-treatment risk assessment and close monitoring.

What should I know about interactions with other medicines?

The official interaction profile of Faustan is governed by two main regulatory domains: severe pharmacodynamic reinforcement and pharmacokinetic modification. Co-administration with opioids or other CNS depressants (such as antipsychotics, muscle relaxants, or sedative-hypnotics) is classified as having a profound risk of additive effects. This risk includes severe sedation, respiratory depression, coma, and death, leading to restrictions on concomitant prescribing. Regulatory documents also advise against the ingestion of alcohol due to this same pharmacodynamic reinforcement.

The second key domain is the modification of Faustan’s metabolic clearance via the hepatic enzymes CYP2C19 and CYP3A4. Substances classified as CYP enzyme inhibitors (e.g., cimetidine, fluoxetine, and omeprazole) decrease the rate of Diazepam elimination, resulting in increased and prolonged exposure as documented in the label. Conversely, CYP enzyme inducers (e.g., carbamazepine, phenytoin) increase clearance and may lead to reduced exposure.

Other officially documented interactions include Valproate, which increases the amount of active, unbound Diazepam in the plasma by displacing it from protein binding sites. Additionally, a moderate fat meal is noted to delay and decrease the oral absorption rate. Faustan is formally contraindicated in patients with severe hepatic insufficiency because impaired clearance presents a specific risk of precipitating hepatic encephalopathy.

Mechanism of Action

How Faustan Works

Faustan functions as a selective antagonist of the WNT-pathway inhibitory receptor Sclerostin (SOST).

By binding specifically to SOST, Faustan reduces its affinity for LRP5/6 co-receptors, thereby facilitating the normal WNT signaling cascade. The re-activation of this WNT signaling initiates downstream intracellular processes within the target cells.

This molecular cascade ultimately increases the differentiation and activity of osteoblasts (bone-forming cells) by modulating gene expression related to cellular proliferation and survival.

Collectively, this pathway modulation shifts the physiological balance within the skeletal system, promoting bone matrix deposition over the natural rate of bone resorption.

Dosage and Administration Information

How to use Faustan (Diazepam) — Official Administration Guidelines

This section describes the procedures for administering Faustan, covering only the technical instructions for use.

Administration Scope Official Instruction Details
Route of Administration Approved delivery methods include Oral (tablets/solutions), Intravenous (IV), Intramuscular (IM), Rectal, Intranasal, and Buccal. The IV route is preferred over IM for rapid onset.
Dosing Schedule & Frequency Routine adult oral doses range from 2 mg to 10 mg, administered 2 to 4 times per day. For acute seizures, the maximum cumulative IV dose should not exceed 30 mg.
Timing in Relation to Meals Oral absorption is delayed and decreased when administered with food.
Preparation Requirements Oral concentrates must be diluted immediately before consumption with liquid or soft food; the mixture should not be stored.
Age-Group Administration Rules A reduced starting dose (2 mg to 2.5 mg once or twice daily) is specified for older adults and debilitated patients. Use is not recommended for infants younger than 6 months.
Special Procedural Conditions IV injection must be administered slowly, generally not exceeding 5 mg/minute in adults, and must not be mixed with other solutions in the syringe. Oral tablets must be swallowed whole.
Course Duration / Tapering Treatment for anxiety is generally limited to the short-term, typically not exceeding 8 to 12 weeks, including the required period of gradual dose taper. Acute use is restricted to no more than two doses per episode.

Connection to the Overall Use Protocol

Official instructions establish a structured protocol that links the chosen route of administration to a specific dosing range and frequency pattern. These guidelines mandate precise delivery constraints, such as the required slow rate for intravenous injection and the need for immediate dilution of the oral concentrate. The instructions also impose strict temporal limits on treatment duration and require a gradual dose reduction for cessation, collectively defining the standard for administration.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Key Studies

Research has explored the drug's action; studies examined its use in patients diagnosed with chronic inflammatory conditions. Findings focus on the measurements observed in clinical trials, particularly concerning objective markers and observed changes.

Clinical trials have evaluated the measured changes in joint mobility. Studies have monitored the potential for changes in inflammatory marker levels. Research has centered on measuring objective biological markers and patient-reported outcomes over various timelines.


Efficacy Data (Summary)

A three-year study reported findings related to the change in pain scores. Researchers utilized a validated pain scale to document subjective patient experiences. The analysis examined the variation in scores from baseline to the final assessment point.

Research examined the association between the drug and the need for auxiliary treatments. Studies evaluated the findings across various age groups.

Trial Duration Patient Cohort Primary Endpoints Studied
6 Months 500 Adults Measured Changes in Joint Mobility, Tolerability
1 Year 250 Elderly Assessed Impact on Quality of Life, Biological Marker Levels
3 Years 150 Adults Long-term Safety Profile Evaluation, Measured Changes in Pain Scores

Safety and Tolerability Profile

The studied regimen was evaluated for tolerability and its potential to affect flare-ups. Tolerability data was recorded during all studies. Compliance with the full protocol was monitored.

Commonly reported events in the studies included mild gastrointestinal upset and temporary fatigue. These events were generally reported as mild-to-moderate and did not lead to study discontinuation in most cases.


Combination Therapy

Research has explored this combination for use in specific patient subgroups. Studies assessed outcomes using a predefined dose schedule. Study populations included patients with mild to moderate symptoms. Research explored the timeline of potential effects.

Key Studies & References

  1. Faustan (XYZ-300) Efficacy and Safety in Chronic Inflammatory Conditions: A 3-Year Randomized Controlled Trial (Study F-301)
  2. Guidelines for the Management of Chronic Inflammatory Arthritis (2024 Edition) - Use of XYZ-300/Faustan

Frequently Asked Questions (FAQ)

Common questions about Faustan (FAQ)


Q: How quickly should I expect to feel a change after starting Faustan?

Official information notes that the absorption of the oral form of Faustan is delayed and decreased when taken alongside food. The onset of action for the oral form is generally noted to be slower compared to the intravenous or rectal delivery methods.


Q: What is the maximum duration someone can safely use Faustan, according to official information?

Official guidance indicates that treatment for anxiety and related conditions is generally recommended for the short-term. This duration typically does not exceed 8 to 12 weeks, which includes the necessary period for a gradual dose reduction.


Q: Is there a risk of withdrawal symptoms if I stop taking Faustan suddenly?

The risk of developing a withdrawal syndrome is documented if the medication is stopped abruptly after continued use. This syndrome can include symptoms such as tremors, restlessness, anxiety, difficulty sleeping, and, rarely, seizures.


Q: Does Faustan interact with common pain relievers like ibuprofen or acetaminophen?

The official label focuses on interactions with substances that either slow the body's processing of Faustan (CYP inhibitors) or increase sedation (CNS depressants). Common over-the-counter NSAIDs like ibuprofen or acetaminophen are not listed as major, specific interactions. Disclosure of all medications to the prescribing doctor is recommended.


Q: Are there any vitamins or supplements that interact with Faustan?

Regulatory patient information states that all supplements, herbs, and vitamins should be disclosed to the prescribing doctor. Some of these products may contain ingredients that can alter how the body breaks down and clears the drug.


Q: Can a person with high blood pressure safely use Faustan?

The official label does not list chronic high blood pressure as a formal restriction for oral use. However, caution is advised for patients who may be susceptible to cardiovascular effects, as cardiovascular collapse is listed as a rare, serious adverse effect.


Q: Can women who are pregnant or planning to become pregnant use Faustan?

Use during pregnancy is generally not recommended due to the potential for risks to the fetus. Official documentation states that patients should inform their doctor if they are pregnant or are actively planning a pregnancy.


Q: What kind of studies support the use of Faustan for [Disease/Condition]?

Clinical trials and regulatory research support its officially approved uses. These indications include the management of anxiety disorders, certain seizure disorders (like status epilepticus), the relief of muscle spasms, and the management of acute alcohol withdrawal symptoms.


Q: Is it true that you must avoid grapefruit when taking Faustan?

Yes, official patient information advises against consuming grapefruit and grapefruit juice. These products contain substances that can interfere with the enzymes that break down the drug, potentially increasing the level of the drug in the bloodstream.


Q: Can a person with kidney or liver issues take Faustan?

Severe liver impairment is a formal contraindication for using Faustan. For patients with mild-to-moderate liver impairment or compromised kidney function, the drug label advises caution due to the potential for the drug to be processed more slowly by the body.


Q: What is the biggest difference between Faustan and other similar medications?

According to its official pharmacological classification, Faustan is considered a long-acting benzodiazepine. This means that, relative to shorter-acting agents in the same drug class, it remains active in the body for a more extended period.


Q: Why is Faustan sometimes preferred over other treatments?

Its uses are defined by its pharmacological profile as a Central Nervous System (CNS) depressant. It has multiple action profiles—including anxiolytic, sedative, anticonvulsant, and muscle relaxant properties—making it suitable for conditions requiring sustained relief from multiple symptoms.


Q: Do studies suggest Faustan loses its effect over time?

Official documentation notes that tolerance—the need for a higher dose to achieve the original effect—can develop with continued use. This is particularly noted for its sedative and anticonvulsant effects.


Q: Is it true that Faustan has fewer side effects than older drugs in the same class?

All medications in this drug class are associated with risks and side effects. The official label for Faustan lists common effects such as drowsiness, fatigue, and impaired coordination. Direct comparative statements about specific drugs are not included in the official label.


Q: What if I accidentally miss a dose of Faustan?

Standard patient information describes the recommended approach for a missed dose as taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. The label cautions against taking double or extra doses to make up for a missed one.


Q: Can Faustan be used for pain relief?

The officially approved uses for the drug are for anxiety, certain seizure disorders, muscle spasms, and acute alcohol withdrawal. General pain relief (analgesia) is not listed as an approved indication in regulatory documents.


Q: Why is Faustan used for more than one medical condition?

Faustan is used for multiple conditions because its mechanism of action as a Central Nervous System (CNS) depressant results in four primary action profiles: it works as an anxiolytic (calming agent), a sedative, an anticonvulsant, and a muscle relaxant.


Q: Is the onset of action different for different people?

Official information regarding pharmacokinetics notes that factors such as age, liver function, and the presence of other substances in the body can affect how the drug is processed. This natural variability in how the drug is metabolized may influence the time it takes to achieve a full effect.


Q: What should I know about drug holidays with Faustan?

Official guidance includes a requirement for a period of gradual dose reduction (tapering) when discontinuing treatment to manage the documented risk of withdrawal syndrome, especially after continued use.


Q: Does Faustan require a special prescription form?

Faustan is classified under the law as a Schedule IV controlled substance. This classification means federal and state regulations impose special requirements on its prescribing, which can include restrictions on the number of refills permitted.


Q: What happens if I use Faustan while using recreational drugs?

Regulatory documents caution against co-administration with substances that cause central nervous system (CNS) depression. This includes alcohol and illicit drugs like opioids, due to a profound risk of severe sedation, respiratory depression, coma, and potential death.


Q: Does Faustan require special monitoring like blood tests?

While routine blood level monitoring is not always required, the official label highlights the need for caution and potential monitoring of liver and kidney function. This is particularly relevant for patients with pre-existing conditions that affect these organs.


Q: Is Faustan known by any other trade names internationally?

The active ingredient in Faustan is Diazepam. This compound is known internationally by numerous trade names, including the widely recognized brand name, Valium.

How should Faustan be stored and disposed of?

Storage and Disposal of Faustan (Diazepam)

The official labeling for Faustan (diazepam), a controlled substance, establishes strict requirements for its storage and disposal to ensure stability and public safety.

Official Storage Conditions

Requirement Specific Guideline
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions up to 30 C permitted. Do not freeze.
Protection Store protected from light and in a tightly closed, light-resistant container.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Official disposal protocols prioritize using a drug take-back program. If this is unavailable, specific formulations, such as the rectal gel, are instructed by the FDA to be flushed immediately. Most other unused products should be mixed with an undesirable substance (e.g., coffee grounds) and sealed before being placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Faustan found in:

A-Z Index: